Sign in or create an account to add this stock to your watchlist.
About Ziopharm Oncology (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, a gene therapy product candidate to treat patients with recurrent glioblastoma. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has collaboration agreements with Precigen, Inc., MD Anderson Cancer Center, the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ZIOP
CUSIP98973P10
Phone617-259-1970
Debt
Debt-to-Equity RatioN/A
Current Ratio7.17
Quick Ratio7.17
Price-To-Earnings
Trailing P/E Ratio-8.51
Forward P/E Ratio-8.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$6.39 million
Price / Sales100.68
Cash FlowN/A
Price / CashN/A
Book Value($0.86) per share
Price / Book-5.24
Profitability
EPS (Most Recent Fiscal Year)($0.53)
Net Income$-54,320,000.00
Net Margins-1,212.13%
Return on EquityN/A
Return on Assets-54.86%
Miscellaneous
Employees46
Outstanding Shares142,650,000
Ziopharm Oncology (NASDAQ:ZIOP) Frequently Asked Questions
What is Ziopharm Oncology's stock symbol?
Ziopharm Oncology trades on the NASDAQ under the ticker symbol "ZIOP."
How were Ziopharm Oncology's earnings last quarter?
Ziopharm Oncology Inc (NASDAQ:ZIOP) released its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.02. The biotechnology company earned $0.15 million during the quarter, compared to the consensus estimate of $1.55 million. View Ziopharm Oncology's Earnings History.
When is Ziopharm Oncology's next earnings date?
What price target have analysts set for ZIOP?
2 brokerages have issued 12 month target prices for Ziopharm Oncology's stock. Their forecasts range from $5.50 to $5.50. On average, they expect Ziopharm Oncology's share price to reach $5.50 in the next twelve months. View Analyst Ratings for Ziopharm Oncology.
What are Wall Street analysts saying about Ziopharm Oncology stock?
Here are some recent quotes from research analysts about Ziopharm Oncology stock:
- 1. According to Zacks Investment Research, "ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. " (5/16/2018)
- 2. HC Wainwright analysts commented, "We note that the biopsy analysis from the tumors of patients with rGBM, presented at SNO 2017, showed that Ad-RTS-hIL-12 plus veledimex monotherapy led to upregulation of PD-1 and PD-L1 receptors, suggesting a potential synergy between IL-12 and anti-PD-1 agents. Together with the shift to combinations, management also intends to expand the Ad-RTS-hIL-12 program beyond recurrent glioblastoma (rGBM) to include additional oncologic indications, such as breast cancer and melanoma. We note that the company plans to present an update of the biopsy analysis from the patients with rGBM and advanced breast cancer treated with Ad- RTS-hIL-12 plus veledimex at ASCO on June 4, 2018." (5/14/2018)
Are investors shorting Ziopharm Oncology?
Ziopharm Oncology saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 34,594,585 shares, an increase of 3.0% from the April 30th total of 35,652,139 shares. Based on an average daily volume of 1,007,107 shares, the days-to-cover ratio is currently 34.4 days. Approximately 27.1% of the company's shares are sold short.
Who are some of Ziopharm Oncology's key competitors?
Some companies that are related to Ziopharm Oncology include Evotec A.G. (EVTCY), Global Blood Therapeutics (GBT), The Medicines (MDCO), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Xencor (XNCR), Corcept Therapeutics (CORT), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK), Spectrum Pharmaceuticals (SPPI), Insmed (INSM), Akcea Therapeutics (AKCA), Puma Biotechnology (PBYI) and AnaptysBio (ANAB).
Who are Ziopharm Oncology's key executives?
Ziopharm Oncology's management team includes the folowing people:
- Dr. Laurence James Neil Cooper Ph.D., M.D., Chief Exec. Officer (Age 53)
- Mr. Kevin G. Lafond, Sr. VP of Fin., CFO, Chief Accounting Officer, Treasurer & Corp. Controller (Age 62)
- Dr. Francois Lebel M.D., Chief Medical Officer and Exec. VP of R&D (Age 66)
- Dr. David M. Mauney M.D., Exec. VP, Chief Bus. Officer & Interim COO (Age 49)
- Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.
Has Ziopharm Oncology been receiving favorable news coverage?
News coverage about ZIOP stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ziopharm Oncology earned a news impact score of 0.21 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.65 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Ziopharm Oncology's major shareholders?
Ziopharm Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.92%), UBS Group AG (0.61%), Schwab Charles Investment Management Inc. (0.47%), Wells Fargo & Company MN (0.18%), Russell Investments Group Ltd. (0.16%) and Summit Trail Advisors LLC (0.09%). Company insiders that own Ziopharm Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for Ziopharm Oncology.
Which institutional investors are selling Ziopharm Oncology stock?
Which institutional investors are buying Ziopharm Oncology stock?
ZIOP stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., UBS Group AG, Summit Trail Advisors LLC, Mackay Shields LLC, Private Advisor Group LLC, Wealthcare Advisory Partners LLC, Wells Fargo & Company MN and Schwab Charles Investment Management Inc.. Company insiders that have bought Ziopharm Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for Ziopharm Oncology.
How do I buy shares of Ziopharm Oncology?
Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ziopharm Oncology's stock price today?
One share of ZIOP stock can currently be purchased for approximately $4.51.
How big of a company is Ziopharm Oncology?
Ziopharm Oncology has a market capitalization of $626.24 million and generates $6.39 million in revenue each year. The biotechnology company earns $-54,320,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. Ziopharm Oncology employs 46 workers across the globe.
How can I contact Ziopharm Oncology?
Ziopharm Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34 NAVY YARD PLAZA, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]
MarketBeat Community Rating for Ziopharm Oncology (ZIOP)
MarketBeat's community ratings are surveys of what our community members think about Ziopharm Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ziopharm Oncology (NASDAQ:ZIOP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Ziopharm Oncology in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible upside of 21.95%. The high price target for ZIOP is $5.50 and the low price target for ZIOP is $5.50. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.67 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.50 | $10.00 | $16.50 | $16.25 |
| Price Target Upside: | 21.95% upside | 147.52% upside | 271.62% upside | 247.97% upside |
Ziopharm Oncology (NASDAQ:ZIOP) Consensus Price Target History
Ziopharm Oncology (NASDAQ:ZIOP) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Ziopharm Oncology (NASDAQ:ZIOP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Ziopharm Oncology (NASDAQ ZIOP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 39.94%
Ziopharm Oncology (NASDAQ ZIOP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/8/2017 | David M Md Mauney | EVP | Buy | 4,270 | $4.68 | $19,983.60 | 58,662 |  |
| 11/8/2017 | Laurence James Neil Cooper | CEO | Buy | 6,440 | $4.68 | $30,139.20 | 1,083,731 | |
| 6/4/2015 | Murray Brennan | Director | Sell | 40,000 | $9.70 | $388,000.00 | | |
| 2/9/2015 | Randal J Kirk | Director | Buy | 1,440,000 | $8.75 | $12,600,000.00 | | |
| 10/29/2013 | Randal J Kirk | Director | Buy | 2,857,143 | $3.50 | $10,000,000.50 | | |
(Data available from 1/1/2013 forward)
Ziopharm Oncology (NASDAQ ZIOP) News Headlines
| Source: |
|
Ziopharm Oncology (NASDAQ:ZIOP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ziopharm Oncology (NASDAQ:ZIOP) Income Statement, Balance Sheet and Cash Flow Statement
Ziopharm Oncology (NASDAQ ZIOP) Stock Chart for Friday, May, 25, 2018
Loading chart…
